Germany puts 300m in CureVac AG for COVID-19 vaccine
In the race aimed at securing access to COVID-19 vaccines, Germany has acquired a minority stake in the local mRNA vaccine producer Curevac AG.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1166 entries already.
Entries by Thomas Gabrielczyk
Abbvie and Genmab team up in oncology
/in News/by Thomas GabrielczykAbbVie is partnering with Genmab A/S to commercialise up to seven new antibody formats.
Evox Therapeutics signs US$1.2bn deal with Eli Lilly
/in News/by Thomas GabrielczykEvox Therapeutics Ltd has licenced its exosome-based RNAi/antisense RNA delivery technology to Eli Lilly to target selected neurological diseases.
Calliditas Therapeutics raise US$90m in Nasdaq IPO
/in News/by Thomas GabrielczykSwedish budenoside formulation specialist Calliditas Therapeutics AB has successfully raised US$90m in an oversubscribed NASDAQ IPO.
Hyloris Pharmaceuticals prepared to go public
/in News/by Thomas GabrielczykBelgian specialty pharmaceutical company Hyloris Pharmaceuticals SA is getting ready to launch an Initial Public Offering at Euronext Brussels.
NodThera bags US$55m in Series B round
/in News/by Thomas GabrielczykNodThera, a Scotch spin-out of Polish Selvita developing oral blockers of the NLRP3 inflammasome blockers, has filled up its cashbox with a US$55m investement.
Bacterial colonisation differs by tumour type
/in News/by Thomas GabrielczykAn analysis of 1.500 tumours demonstrates that different human tumour types each harbour their own unique bacterial communities.
Novo Holdings invests into AI CRO ExScientia
/in News/by Thomas GabrielczykNovo Holdings leads the current US$60m Series C round of ExScientia Ltd, the world-leading artificial intelligence (AI)-driven drug discovery company.
Poxel SA raises 17.7m through capital increase
/in News/by Thomas GabrielczykMetabolic disease specialist Poxel SA has announced a private placement of 2,358,483 new ordinary shares at 0.02 per share reserved to specified investors.
British scientists start Phase II on COVID-19 vaccine
/in News/by Thomas GabrielczykResearchers at the University Oxford and AstraZeneca have started enrolment for a Phase II/III trial to test a COVID-19 vaccine in 10,000 volunteers.